Epizyme (NASDAQ:EPZM) received a $27.00 price objective from equities researchers at Oppenheimer in a research note issued to investors on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective would indicate a potential upside of 249.29% from the stock’s current price.
Several other research firms also recently issued reports on EPZM. SunTrust Banks lifted their price target on Epizyme to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 25th. BidaskClub downgraded Epizyme from a “hold” rating to a “sell” rating in a research note on Thursday, July 26th. Roth Capital set a $18.00 price target on Epizyme and gave the stock a “buy” rating in a research note on Monday, October 22nd. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. Finally, Zacks Investment Research downgraded Epizyme from a “buy” rating to a “hold” rating in a research note on Thursday, July 19th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $20.55.
Shares of NASDAQ EPZM traded down $0.69 during trading on Friday, hitting $7.73. 31,904 shares of the company were exchanged, compared to its average volume of 808,096. The firm has a market capitalization of $662.27 million, a P/E ratio of -3.56 and a beta of 1.64. Epizyme has a 1 year low of $7.74 and a 1 year high of $21.40.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.11. The firm had revenue of $12.00 million for the quarter, compared to analyst estimates of $0.54 million. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.48) EPS. As a group, equities research analysts forecast that Epizyme will post -2.11 earnings per share for the current year.
In other news, Director David M. Mott bought 416,667 shares of the business’s stock in a transaction that occurred on Friday, October 5th. The stock was purchased at an average price of $9.00 per share, with a total value of $3,750,003.00. Following the purchase, the director now owns 12,088 shares of the company’s stock, valued at approximately $108,792. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 21.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in EPZM. Principal Financial Group Inc. acquired a new position in Epizyme in the 1st quarter valued at about $187,000. BB&T Securities LLC raised its stake in Epizyme by 45.5% in the 2nd quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 5,000 shares during the last quarter. Jane Street Group LLC acquired a new position in Epizyme in the 1st quarter valued at about $273,000. BlueMountain Capital Management LLC acquired a new position in Epizyme in the 2nd quarter valued at about $320,000. Finally, Trexquant Investment LP acquired a new position in Epizyme in the 2nd quarter valued at about $328,000. 74.11% of the stock is owned by hedge funds and other institutional investors.
Epizyme Company Profile
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Recommended Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.